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Summary
It is highly desirable to design ligand-dependent tran-
scription regulation systems based on transactivators
unresponsive to endogenous ligands but induced by
synthetic small molecules unable to activate endoge-
nous receptors. Using molecular modeling and yeast
selection, we identified an estrogen receptor ligand
binding domain double mutant (L384M, M421G) with
decreased affinity to estradiol and enhanced binding
to compounds inactive on estrogen receptors. Nonre-
sponsiveness to estrogen was achieved by addition-
ally adding the G521R substitution while introducing
an “antagonistic-type” side chain in the compound,
as in 4-hydroxytamoxifen. The triple-substituted li-
gand binding domain is insensitive to physiological
concentrations of estradiol and has nanomolar affin-
ity for the ligand. In this binary system, both receptor
and ligand are, therefore, reciprocally specific. The
mutated variant in the context of a chimeric transcrip-
tion factor provides tight, ligand-dependent regula-
tion of reporter gene expression.
Introduction
Several artificial systems that allow inducible expres-
sion of a transgene in response to small molecule li-
gands have been developed (reviewed in [1, 2]). These
systems usually rely on two components. The first is a
chimeric transcription factor obtained by fusing a DNA
binding domain (DBD) to a transcription activation do-
main (AD) and to a regulatory domain that interacts with
a small molecular weight compound that acts as an
inducer drug. The second component is an artificial
promoter consisting of multimeric binding sites for the
DBD followed by a minimal promoter sequence. The
chimeric transcription factor is recruited to (or in some
cases released from) the specific target promoter upon
interaction with the exogenously added drug: transcrip-
tion of a transgene cloned downstream of this promoter
can thus be modulated in vivo by drug delivery or with-
drawal.
An ideal ligand-dependent transcription system must*Correspondence: paola_gallinari@merck.comdisplay a low basal activity and high inducibility: more-
over, it should be activated in a dose-dependent man-
ner by the inducer ligand. However, two additional cri-
teria must be fulfilled for long-term gene therapy
applications in humans. First, the chimeric activator
should not be immunogenic; second, the inducer drug
should display an appropriate safety profile and should
not interfere with endogenous metabolic pathways [1].
Steroid receptors are composed of distinct and func-
tionally independent domains with intrinsic DNA bind-
ing, transactivating, and ligand binding properties [3].
Inducible chimeric transactivators that function indepen-
dently of endogenous steroids have been constructed by
using mutant forms of the ligand binding domains
(LBDs) of the progesterone receptor (PR) and of the
estrogen receptor (ER) that are not responsive to their
natural ligands but are induced by synthetic antago-
nists such as RU486 and 4-hydroxytamoxifen (4-OHT),
respectively [4–8]. According to this strategy, we have
recently generated a novel, to our knowledge, human-
ized gene switch specifically designed to work in mus-
cle cells [9]. This system includes a 4-OHT-dependent
chimeric transactivator, called HEA, composed of three
elements derived from human proteins: the DBD of the
human transcription factor hepatocyte nuclear factor-1
(HNF-1), a G521R mutant version of the human ERα-
LBD, and the AD from the human transcription activator
NF-kB p65. HEA binds and activates an artificial pro-
moter containing multimeric HNF1α binding sites in a
ligand-dependent manner. When delivered in vitro and
in vivo to muscle cells that lack endogenous HNF-1,
HEA displays a low basal activity and is efficiently acti-
vated after exposure to 4-OHT.
Built from components of human origin, the HEA sys-
tem has a low potential to elicit an immune response in
humans: however, prolonged administration of its in-
ducer drug tamoxifen (TAM), the immediate precursor
of 4-OHT, raises safety concerns for human gene ther-
apy. TAM is currently used to prevent recurrence of
breast cancer, and the HEA system is activated in mice
by TAM dosages comparable to those used in clinical
practice ([9] and references therein). Nonetheless, pro-
longed treatments with TAM are associated with a well-
defined increased risk of endometrial cancer due to its
partial agonist activity on endogenous ERα in tissues
other than the mammary gland [10, 11]. Therefore, an
inducer drug that does not show any binding to endog-
enous ERs would be appropriate for long-term gene
therapy in humans.
These considerations prompted us to redesign the
ER-LBD hormone interface in order to differentiate it
from endogenous receptors and to identify cognate li-
gands that only bind this mutant LBD. Reengineering
ligand-receptor pairs to generate functionally ortholo-
gous transcriptional regulators was proven to be feasi-
ble with the ER-LBD interface [12–14]. To this purpose,
both groups made a limited number of coordinated
changes into the full-length receptor and its natural li-
gand with a focus on the A ring of estradiol (E2). Ideally,
however, it would be important to generate a broad
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884class of novel nonsteroidal ligands with enhanced
specificity features.
To this aim, we have developed an alternative strat-
egy. We started by identifying, within a series of active
ER ligands, compounds inactive on both ERα and ERβ.
By combining molecular modeling and screening of a
library of ER mutants, we identified a novel, to our
knowledge, class of ligands with high affinity and speci-
ficity for a triple-substituted ERα-LBD. Grafting this
mutant into the HEA transcription factor allowed for
highly selective and efficient transcriptional induction
in mammalian cells.
Results
Rational Design and Construction of a Compound-
Specific ER-LBD Mutant Library
Our goal was to modify the ER-LBD so that it was un-
able to bind natural ligands, such as E2, but able to
bind and be activated in the context of a chimeric tran-
scription factor by a synthetic analog unable to bind
the natural ER. In the search for candidate starting
compounds, we looked at two essential criteria. First,
the candidate should be inactive against both hERα
and hERβ within an otherwise generally active series.
Second, the structural features of the candidate should
require only a limited modification around the ligand
binding pocket of the hERα-LBD.
We synthesized CMP1 (Figure 1A), a tetrahydrofluo-
renone with a benzyl substituent at the 9a position.
Tetrahydrofluorenones without the benzyl group, like
CMP2 and 3 (Figure 1A), are otherwise nanomolar se-
lective binders and activators of hERβ. Introduction of
a large substituent such as benzyl at the C9a position
has been found to result in a substantial loss of binding
affinity for both hERα and hERβ ([15, 16]; R.R. Wilkening
et al., personal communication; Table 1). The newly
synthesized CMP1 indeed displayed a very poor bind-
ing affinity for both hERα and hERβ (IC50 values > 104
nM) and therefore represented a promising starting
point around which a receptor mutagenesis strategy
could be designed.
X-ray structures of agonist bound hERα- and hERβ-
LBDs [17–19] were used to model CMP1 into the re-
spective binding pockets by superimposing the tetra-
hydrofluorenone scaffold with that of the active analogs
in the crystal structures. According to modeling of the
free, unbound CMP1, three almost isoenergetic confor-
mations of the 9a benzyl substituent were considered
(Figure 1B). The superposition defined an area of the
protein that clashes with the benzyl substituent of the
tetrahydrofluorenone. Five residues within the ligand
binding pocket were identified as the most likely candi-
date residues interfering with binding of CMP1: L391/
L343, F404/F356, M421/I373, I424/I376, and L428/L380
of hERα/hERβ, respectively. A mutant library including
these five positions should cover nearly 300° of confor-
mational space of the 9a benzyl rotamer, including all
three major conformations. Because the interference
with binding of CMP1 is expected to arise from steric
clashes between side chains and the 9a benzyl moiety,
substitutions into smaller amino acids should remove
this hindrance. At the same time, however, these changes
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Tould also destabilize the pocket, which would require
ome compensatory substitution at neighboring resi-
ues. Due to the generally hydrophobic character of
oth the binding pocket and the benzyl substituent, we
herefore decided to use only G, A, C, V, I, L, M, F, Y, or
as possible substitutions at each of the five posi-
ions.
We have recently reported the generation of a 4-OHT-
nducible, ERα-based humanized switch [9]. The selec-
ivity of tetrahydrofluorenones for ERβ therefore consti-
uted an additional issue to take into account for the
eneration of a new orthogonal switch based on the
Rα-LBD. According to the crystal structures of hERα
nd hERβ [17–19], the tetrahydrofluorenones selectivity
ould be conferred by the two residues (individually or
n combination) that differ in the ligand binding pockets
f the two receptors, i.e., L384/M336 and M421/I373 in
ERα/hERβ, respectively. M421 corresponded to one of
he positions mutated in the library (see above), and
nclusion of Ile as a possible substitution automatically
ntroduced the wild-type (wt) hERβ residue into the li-
rary. For the second residue, we decided to generate
he library in the context of a L384M-mutated hERα. To
onfirm our predictions, we performed in vitro radioli-
and displacement assays by using GST fusion con-
tructs with single L384M or combined L384M/M421I
ubstitutions in the hERα-LBD (hereafter called M-ERα-
BD and MI-ERα-LBD, respectively). The results show
hat both L384M and L384M/M421I mutants have sig-
ificantly improved binding to the agonists CMP2 and
MP3 as compared to wt ERα (Table 1).
eneration and Characterization of a Yeast Library
n the ER Ligand Binding Pocket
n order to genetically select for CMP1-responsive vari-
nts, both wt and M-ERα-LBD were fused to the GAL4
NA binding domain (DBD) and the VP16 transactiva-
ion domain (Figure 2A) to generate hybrid transcription
actors. These were transfected in the yeast strain
G1945 to measure their β-galactosidase transactiva-
ing potential in the presence of E2 or CMP2. While both
onstructs were equally sensitive to E2, the responsive-
ess of the L384M chimera to CMP2 was, as expected,
uperior to that of the wt (Figure 2B). This test also
emonstrated that tetrahydrofluorenones are able to
ross the yeast membrane.
Generation of the library of M-ERα-LBD variants took
dvantage of the inherent yeast recombination system.
wo oligonucleotides degenerate for ten different amino
cids at each of the five library positions were synthe-
ized by using a dinucleotide assembly strategy [20]
hat also included sufficiently long (>30 bp) constant
lanking regions to direct the homologous recombina-
ion. To decrease the likelihood that clones with single
r double mutations would be lost during synthesis,
onstruction, or selection of the library, the concentra-
ion of wt codons was raised to 15% for each of the
utated positions. As a consequence, the relative abun-
ance of 1 or 2 residue variants was significantly raised
by about 5- and 3-fold, respectively) compared to only
minor reduction in the relative abundance of 5 residue
ariants (to 0.8-fold) (see Experimental Procedures).
his strategy was guided by modeling predictions that
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885Figure 1. Design of a Compound-Specific ER-
LBD Mutant Library
(A) Structures of estradiol and representative
active and inactive tetrahydrofluorenone an-
alogs. Positions 4 and 9a, where substituents
have been introduced, are indicated.
(B) hERα-LBD mutant library. Molecular mod-
els of the three rotamers of CMP1 in the crys-
tal structure of the hERα (PDB entry 1ERE)
binding pocket. The five residues mutagen-
ized in the library are shown together with
G521. Left: solvent-accessible surface of CMP1.
Right: space-filling representation highlighting
the steric clashes between side chains and
CMP1. Side chains of library residues are
colored yellow.sen clones revealed the expected library complexity
Table 1. Binding Specificities of E2 and of Active and Inactive Tetrahydrofluorenones
Binding (IC50, nM)
Compounds wt hERα wt hERβ GST-wt ERα-LBD GST-M ERα-LBD GST-MI ERα-LBD GST-MG ERα-LBD
E2 1.6 (± 0.2) 1.4 (± 0.2) 2.3 (± 0.34) 5 (± 0.53) 0.7 (± 0.1) 46 (± 4.4)
CMP2 676 (± 82) 6 (± 0.8) 800 (± 85) 48 (± 5) 42 (± 3.75) nd
CMP3 223 (± 30) 4 (± 0.45) 780 (± 103) 45 (± 5.5) 68 (± 8.4)) nd
CMP1 >10,000 >10,000 >10,000 >10,000 nd 3,900 (± 413)
CMP4 1,470 (± 197) 506 (± 63.3) 2,320 (± 225) 1,480 (± 133) nd 12 (± 1.85)
CMP5 >10,000 1,247 (± 141) >10,000 >10,000 nd 155 (± 18)
Average values of three or four experiments (± standard deviation); nd: not determined.
receptor. Interestingly, no clones containing the M421Isuggested that predominantly 1 or 2 residue variants
rather than multiple changes would be sufficient to ac-
commodate the CMP1 ligand and, at the same time, be
tolerated by the LBD structural framework.
Preparative amounts of mutated LBD fragments were
synthesized by PCR amplification of the hERα-LBD
template by using the degenerated oligonucleotide
mix. The mutated fragment collection was then in-
cluded in a scaled up cotransformation experiment to-
gether with a linearized recipient M-ERα-LBD vector.
Approximately 106 colonies corresponding to a 10-fold
library redundancy were plated, and 12 randomly cho-(data not shown). In order to probe the library for selec-
tion capacity, −His/−Trp growth-selective plates were
treated with increasing amounts of the hERβ agonist
CMP3. Sequencing of nine randomly picked clones in-
dicated that, unlike with the nonselected clones, most
of the CMP3-selected clones had either none or few
amino acid substitutions at all five mutagenized posi-
tions; two of these positions, L391 and M421, are com-
pletely conserved (data not shown). It appears there-
fore that a very restricted number of mutations is
tolerated in the hER binding pocket to maintain a pro-
ductive interaction with a high-affinity ligand of the wt
Chemistry & Biology
886Figure 2. Comparison of Chimeric Transcription Factors Containing
wt hERα-LBD or hERα-L(384)M-LBD
(A) Schematic representation of the GAL4DBD/hERα-LBD/VP16AD
chimeric transcription factors.
(B) Transcriptional activation in yeast transformants expressing chi-
meras based on wt hERα-LBD (squares) or hERα-L(384)M-LBD (cir-
cles) by E2 and the hERβ-specific compound CMP2. Dose-response
curves of β-galactosidase activity in the presence of increasing
concentrations of E2 or CMP2 were obtained. EC50 values were
determined as described in Experimental Procedures.
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Csubstitution were selected. This finding is in agreement
with the observation that no further increase in binding
affinity for CMP3 was observed by adding this second
substitution to the L384M-mutated protein (Table 1).
Genetic Selection of ER-LBD Variants
Having confirmed the expected composition and re-
sponsiveness of the library, we performed first growth
selection in the presence of the inactive analog CMP1
at a concentration of 1 M. A total of 1600 independent
clones were subsequently screened against 1 M CMP1
or DMSO as a control on −Trp/X-gal-containing plates.
A total of 54 independent clones were judged positive
for β-galactosidase transactivation, and 28 of these
also retained positivity in the presence of 0.1 M
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tMP1. A subsequent selection was carried out by
sing the same strategy but by performing the initial
rowth selection and first round of white/blue screening
n the presence of a 10-fold higher compound concen-
ration (10 M). A total of 31 clones retained positivity
hen challenged with 0.1 M CMP1 and were therefore
elected for further characterization together with the
nitial 28 positive clones.
DNA sequence analysis revealed a consensus se-
uence of the selected mutant variants (Table 2). The
ost prominent feature was the mutation of M421 into
smaller side chain residue (mostly into G and to a
esser extent into A) that occurred in 86% of the se-
ected clones. Importantly, this mutation was never ob-
erved in clones selected by using the agonist CMP3
data not shown), thus excluding a bias in the screening
rocedure. The isolated M421G mutation was found
ith a relatively low frequency and was more often pre-
ent in combination with a substitution of I424 to M, V,
r L. In addition, a third mutation of F404 to W was
ound in 28% of the mutated clones. Finally positions
391 and L428 were generally conserved. The consen-
us sequence present in most selected variants is con-
istent with a model in which the benzyl substituent of
MP1 is directed toward the positions originally occu-
ied by M421 and I424 (Figure 1B, rotamer 1). Western
lot analysis of yeast protein extracts from all represen-
ative clones shown in Table 2 by using a monoclonal
ntibody directed against VP16 AD did not show signifi-
ant differences in the expression levels of the corre-
ponding chimeric proteins (not shown).
Yeast-Selected ER-LBD Variant Mutated in M421
s Preferentially Bound and Transcriptionally
ctivated by Benzyl Tetrahydrofluorenones
elected mutations shown in Table 2 were introduced
n the pGEX-M-ERα-LBD prokaryotic expression con-
truct, and the corresponding GST fusion protein variants
ere expressed in E. coli. Suitable aliquots of crude bac-
erial extracts containing comparable amounts of all dif-able 2. DNA Sequence Analysis of Plasmids Rescued from the
enetically Selected Variants
Number of
L391 F404 M421 I424 L428 Clonesa
L F G I L 5
L W G I L 2
L F G M L 9
L W G M L 2
M W G M L 1
L F G V L 11
W G V L 2
F G V L 1
F G L L 5
W G L L 3
W G L L 1
W A L L 1
W A L L 1
hree wt sequences and six mixed sequences were also identified
ut are not included. All amino acids found in selected variants that
iverge from the wild-type ERα-LBD sequence are shown in bold.
The number of independent clones in which the same mutation
rray was found is indicated.
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887ferent protein variants were tested for binding in vitro
to increasing concentrations of 3[H] E2. All variants
bound the natural ligand E2 with reduced affinity com-
pared to the M-ERα-LBD protein (data not shown). The
mutant carrying the additional selected single substitu-
tion M421G (hereafter called MG-ERα-LBD) bound E2
with a kd value approximately 9-fold higher than that of
M-ERα-LBD (46 nM and 5 nM, respectively) (Table 1).
The kd value for the hormone was in a range suitable
to measure the affinity of MG-ERα-LBD for a series of
benzyl-substituted tetrahydrofluorenones, CMP1, CMP4,
and CMP5 (Figure 1A), in 3[H] E2 displacement assays.
The glycine in position 421 conferred increased binding
to all benzyl-substituted compounds tested (Table 1).
The affinity for the phenolic tetrahydrofluorenone CMP4
was significantly higher than for the corresponding pyr-
azole analog CMP5. Furthermore, the binding affinity
was higher for CMP5, with a methyl group in position
4, than for CMP1, possessing a hydrogen atom in the
corresponding position. Interestingly CMP4 and E2
showed reversed binding affinities for the double mu-
tant MG-ERα-LBD as compared to wt ERα and ERβ re-
ceptors.
To confirm this partial selectivity at the transcriptional
level, GAL4/VP16 chimeras containing M-ERα-LBD or
MG-ERα-LBD were tested in ligand-dependent β-galac-
tosidase transactivation experiments in the presence of
E2, CMP4, or CMP5. The results shown in Figure 3 con-
firm that only MG-ERα-LBD was activated preferentially
by both CMP4 and CMP5, with EC50 values of 36 nM
and 217 nM, respectively, comparable with the IC50 val-
ues measured in vitro. Its response to E2 (EC50 = 1.5
nM) was approximately 8-fold higher than that associ-
ated with the parental clone (EC50 = 0.2 nM), a differ-
ence of the same order of magnitude of that measured
in vitro (see Table 1).
M384 was backmutated to L in the context of the
M421G-selected mutant, thus generating a single-sub-
stituted G-ERα-LBD. The transcriptional activity in-
duced in yeast by CMP5 was strongly impaired in the
absence of the L384M change (data not shown), indi-
cating that both amino acid substitutions were neces-
sary to define the ligand specificity of the selected
mutant.
In conclusion, binding and transcriptional activity data
taken together show that the introduction of only two
amino acid substitutions, L384M/M421G, impart the
desired orthogonality shift when combined with benzyl-
substituted tetrahydrofluorenones. These two changes,
however, are insufficient to reduce binding to E2 to de-
sirable levels.
Introduction of the G521R Mutation into the MG-
ER-LBD Causes Loss of Binding to E2
and Selective Induction by “Antagonistic
Chain”-Substituted Tetrahydrofluorenones
Estrogen receptors bearing the G521R substitution in
their LBD exhibit low basal transcriptional activity,
strongly reduced affinity for E2, but intact binding and
activation by 4-OHT [21, 22]. More generally, ligands
such as tamoxifen or raloxifene, which have an “antag-
onistic tail,” can apparently compensate for loss of af-
finity introduced by G521R in the ligand binding pocket.Figure 3. Ligand-Dependent Transcriptional Activity of the
M(421)G-Selected Mutant in the lacZ Reporter Yeast Strain Y187
Dose-response curves of β-galactosidase activity in the presence
of increasing concentrations of E2 and the two tetrahydrofluore-
none compounds CMP4 and CMP5 were determined for the
L(384)M, M(421)G-selected mutant (squares) and for the L(384)M
parental clone (circles). EC50 values were calculated as described
in Experimental Procedures.This property has been at the basis of the recent gener-
ation of a tamoxifen-dependent transcription switch [9].
A new series of compounds was generated by sub-
stituting the methyl group in position 4 with more bulky
side chains mimicking an “antagonistic tail” ([15]; R.R.
Wilkening et al., personal communication; Figure 4A).
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888Figure 4. Orthogonal Gene Switch in Mammalian Cells
(A) Structures of representative “antagonistic chain”-substituted
tetrahydrofluorenones.
(B) Representative dose-response curves of chimeric transcription
factor HEA-MGR to CMP8 (squares) and E2 (triangles).
(C) HEA-MGR response to “antagonistic chain”-substituted tetra-
hydrofluorenones.
Each data point represents the mean ± SD of three independent ex-
periments.
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aBoth pyrazole (CMP9) and phenol derivatives (CMP6,
CMP7, CMP8, and CMP10) containing different side
chains were challenged in competitive radiometric
in vitro assays for binding to MG-ERα-LBD or to wt
ERα-LBD (Table 3). All compounds showed nanomolar
affinity for the double mutant (22–107 nM) and signifi-
cant selectivity over wt LBD and both α and β full-
length ER, albeit to different extents. Selectivity ranged
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ietween 50- and 150-fold, the differences being some-
hat less pronounced on the full-length receptors. The
ighest selectivity was observed for CMP8, suggesting
hat substituents other than chloride at the benzyl para-
osition might be explored to further increase selectiv-
ty. Lack of the M421 side chain in the MG-ERα-LBD
pparently generates enough space to also accommo-
ate a substituted benzyl group. On the contrary, the
bserved loss in affinity of the wt ER-LBD for CMP10
as further accentuated with the Cl-substituted CMP8
Table 3). Overall, these data indicate that the specific-
ty conferred by the M421G substitution for the benzyl
roup in the 9a position of tetrahydrofluorenones (Table
) is maintained in antagonistic chain-substituted li-
ands.
This evidence prompted us to generate a triple-sub-
tituted LBD carrying G521R in the context of MG-ERα-
BD (hereafter called MGR-ERα-LBD). We reasoned
hat if this mutant maintains high-affinity binding to “an-
agonistic chain”-substituted benzyl tetrahydrofluore-
ones, the system would show all of the desired prop-
rties for a functionally orthogonal ligand-dependent
ystem, i.e., low affinity of the mutant receptor for E2,
nd high-affinity binding of the same mutated receptor
or a set of compounds with strongly decreased bind-
ng to the wt receptor. As expected, MGR-ERα-LBD
oes not bind to E2 (data not shown). However, this
roperty did not allow for measuring direct binding of
MP6 to CMP10 in the competitive radiometric in vitro
ssay. Hence, the selective response of MGR-ERα-LBD
o the antagonist tetrahydrofluorenones was ascer-
ained in yeast (Figure S1; see the Supplemental Data
vailable with this article online).
To test the system directly in mammalian cells, we
odified the ligand-dependent transcription regulator
EA-1 [9] by replacing the G521R mutant hERα-LBD
ith MGR-ERα-LBD. The new construct was cotrans-
ected in HeLa cells along with the reporter plasmid
xH1/CRP/SEAP [9]. Cells were treated with increasing
oncentrations of four antagonistic compounds (CMP6,
MP8, CMP9, and CMP10), and SEAP levels were mea-
ured in the culture medium after 24 hr of treatment
Figure 4C). The chimera was stimulated by all four
ompounds in a dose-dependent manner. A represen-
ative dose-response curve with CMP8 (the compound
howing the highest degree of selectivity, Table 3) is
hown in Figure 4B. In the absence of treatment, a
asal SEAP level of 0.8 ± 0.2 ng/ml was measured, and
his level is similar to that measured in the culture me-
ium of cells transfected only with the reporter plasmid
data not shown). This indicated the absence of a sig-
ificant basal activity in this experimental setting.
bout 1900 ng/ml SEAP was measured at the highest
oncentrations of CMP8, which corresponds to about
2000-fold increase as compared to the uninduced
ondition. Similar induction levels were consistently
bserved in duplicate experiments and with all four
ompounds (data not shown). Figure 4B also shows
hat the chimera is minimally activated by E2 only at the
ighest supraphysiological concentrations of the hor-
one (17-fold and 50-fold induction at 500 nM and 1
M E2, respectively). Consistent with the in vitro bind-
ng analysis (Table 3), CMP9 displayed the lowest activ-
ty with an EC of approximately 300 nM, while the50
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889Table 3. Binding Specificity of “Antagonistic Chain”-Substituted Tetrahydrofluorenones
Binding (IC50, nM) Selectivity (IC50 ratios)
GST-MG GST-wt wt ERα-LBD/ wt hERα/ wt hERβ/
Compounds ERα-LBD ERα-LBD wt hERα wt hERβ MG-LBD MG-LBD MG-LBD
CMP6 29 (± 3.5) 1371 (± 186) 223 (± 22) 96 (± 22) 47 7.7 3.3
CMP7 25 (± 3.5) 1306 (± 127) 259 (± 39) 307 (± 42) 52 10.4 12.3
CMP8 29 (± 2.8) 4436 (± 643) 1085 (± 121) 2232 (± 230) 153 37.4 77
CMP9 107 (± 11) 1126 (± 140) 622 (± 94.5) 125 (± 13) 11 5.8 1.2
CMP10 22 (± 3) 1272 (± 168) 375 (± 41) 184 (± 23) 58 17 8.4
Average values of three or four experiments (± standard deviation).EC50 of the other compounds ranged from 11 to 40 nM
(Figure 4C).
Discussion
Engineering of protein-ligand interfaces is emerging as
an important approach for creating new tools to study
and manipulate a variety of biological systems (re-
viewed in [23]). This concept is being applied in the
design of enzymes with novel substrate specificities, to
the control of processes such as apoptosis, recombina-
tion, and signal transduction, or to the provision of tem-
poral control of gene expression. The purpose of our
study was to broaden the repertoire of reagents capa-
ble of triggering ligand-induced transcription control of
a transduced transgene, with the potential for an addi-
tional application in somatic gene therapy. The system
we chose was the estrogen receptor LBD. Using a com-
bination of rational design and yeast genetic selection,
we generated an ERα-LBD variant specific for a lead
compound not recognized by the wt receptor. Addi-
tional mutations led to the loss of recognition by the
endogenous ligand and required the introduction of
compensatory changes in the novel, to our knowledge,
class of synthetic ligands.
Although the generation of functionally orthologous
ligand-ER pairs had already been reported before [12–
14], a major distinguishing feature of our work relies on
the use of an entirely new, to our knowledge, class of
compounds structurally unrelated to existing natural li-
gands. We applied a new, to our knowledge, strategy
that employs structural information to identify a region
of the receptor for modification, followed by generation
of a library of mutants in this region and genetic selec-
tion in yeast. The ER is unique among steroid receptors
in its ability to embrace a wide variety of nonsteroidal
compounds. Although the “pincer-like” arrangement
around the A ring imposes a general requirement for
ligands to contain an aromatic ring, the remainder of
the binding pocket can accept a variety of hydrophobic
groups [17, 24, 25]. This promiscuity can be attributed
to the size of the cavity, which has a probe accessibility
of up to 450 A3, which is nearly twice the volume of E2
(245 A3). From the various ER binders, we chose tetra-
hydrofluorenones as an emerging series of small li-
gands ([15, 16]; R.R. Wilkening et al., personal com-
munication). Different from E2, these compounds have
a five-membered ring in position B and lack ring D. Al-
though active compounds of this series are up to 400-
fold more selective for ERβ (data not shown), a singleamino acid change in the ERα ligand binding pocket
(L384M) converted them into acceptable binders that
could be used for further evolution.
Our initial strategy was based on a bump/hole ap-
proach that used an inactive compound carrying a
bulky hydrophobic benzyl substituent combined with
the strategy of generating additional space within the
binding pocket. Modeling of this compound into the
ER-LBD cavity led us to predict potential steric clashes
with a restricted number of amino acid residues. Con-
struction and selection of a library of mutated ERα-
LBDs in yeast allowed us to explore simultaneously a
large surface area around the bulky substituent and to
identify M421 as a key residue. The substitution of
M421 by amino acids with smaller side chains provided
the highest gain in binding energy. This strongly vali-
dates the strategy that guided the library design con-
firming our prediction that the target compound should
adopt only a few distinct conformations. Furthermore,
through genetic screening of the mutant library, only
one conformation was unambiguously selected, namely,
the one having the benzyl substituent directed toward
M421. The double-substituted LBD L384M/M421G rep-
resented a significant progress toward the desired shift
in specificity since it proved to bind the cognate ligand
CMP4 better than E2. Conversely, CMP4 showed a 122-
and 42-fold binding selectivity for the cognate receptor
LBD L384M/M421G over wt ERα and ERβ, respectively.
The final step was the introduction of a well-charac-
terized substitution in ERα, namely, G521R, which is
known to strongly reduce binding to E2 when present
in the context of the wt receptor, while still allowing
binding of compounds such as 4-OHT that carry a
bulky side chain [21]. Crystal structures for 4-OHT and
raloxifene bound to the wt receptor have shown that
the bulky side chains are too long to be contained
within the binding cavity [17, 18]. Instead, they protrude
from the pocket between helix 3 and 11, displace helix
12, and establish additional contacts with a variety of
residues. These additional contacts are believed to
compensate for rearrangements that take place in the
LBD as a consequence of the G521R substitution. We
believe that the situation is similar with the “antagonis-
tic” side chain at the 4 position of tetrahydrofluorenone
derivatives CMP6–CMP10. Among these, all compounds
with a hydroxyphenyl moiety bound MG-ERα-LBD with
significantly high affinities (10−8). CMP8 showed the
highest selectivity for MG-ERα-LBD versus wt ERα or
ERβ (37- and 77-fold, respectively).
The final assessment of the new orthogonal receptor-
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transcriptional induction of a reporter transgene in
mammalian cells. This was done by grafting the MGR-
ERα-LBD into the previously characterized hybrid tran-
scription activator HEA-1 and transfecting it into HeLa
cells. The results show that this new transcription
switch is highly sensitive to low concentrations of
CMP8 and is fully silent over a wide range of physiolog-
ical and supraphysiological concentrations of E2. Inter-
estingly, association constants determined in vitro pre-
cisely correlate in our study with the observed EC50
values in HeLa cells for both the “antagonistic” side
chain tetrahydrofluorenone derivatives and E2. The
same degree of correlation was not observed pre-
viously for a different ERα orthogonal ligand-receptor
pair for which transactivation studies in cells were per-
formed by using the entire receptor [14]. In that case, it
was postulated that differential interactions with cellu-
lar accessory proteins can reduce the receptor selectiv-
ity of the ligand compared to its intrinsic binding selec-
tivity measured in vitro. In our study, the use of a
synthetic transactivator carrying only the ERα-LBD can
minimize interaction with these accessory proteins.
This in turn may render the in vitro and in vivo systems
closer to each other and permit a better uniformity in
the data.
Functionally orthologous ligand-receptor pairs have
been generated in the past years for a variety of tran-
scriptional switches useful in gene therapy [26–31]. Im-
provements in our knowledge of protein-protein and
protein-ligand interactions are leading to constant en-
hancement in the selectivity of these systems, and the
data presented in this paper provide further support to
this concept. The final goal of these efforts is the gener-
ation of new compounds that combine selectivity with
acceptable pharmacological properties, which would
allow for oral delivery at acceptable doses but would
not result in systemic toxicity. This will require further
refinements and optimizations of the described lead
compounds similar to those currently applied to stan-
dard drug discovery.
Significance
Controlled regulation of transcription by exogenous
synthetic ligands acting on a specific transactivator
has important applications in a large spectrum of bio-
logical systems, from in vitro cell culture to living or-
ganisms. A highly desired property of such a system
is to minimize interference with the host system that
could arise as a consequence of introducing an exog-
enous receptor and/or ligand. A binary system in
which both receptor and ligand are reciprocally spe-
cific, recognizing only each other, would fulfill this
requirement. However, in living organisms, introduc-
tion of an exogenous receptor will, in general, induce
an immune response. Likewise, use of an endogenous
receptor can affect accessory proteins through resid-
ual protein-protein interactions. Here, we describe,
starting from the estrogen-receptor ligand binding
domain, the stepwise design of a receptor-ligand sys-
tem that requires only minimal modification of the en-
dogenous receptor in order to become responsive to
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(he synthetic ligand while nonresponsive to the en-
ogenous estrogen ligand. Choice of a class of com-
ounds inactive on the wt estrogen receptors isolates
ur system and avoids interference with endogenous
strogen activity. In order to minimize interaction with
strogen-receptor accessory proteins, we designed a
odular synthetic transactivator combining the modi-
ied ligand binding domain with heterologous DNA
inding and transactivation domains. The resulting
himeric transcription factor enabled tightly con-
rolled ligand-dependent gene expression in mamma-
ian cells. Further optimization of the described lead
ompounds with respect to their pharmacological
roperties should allow for oral delivery at acceptable
oses in living organisms.
xperimental Procedures
rganic Chemistry
ynthesis methods for compounds CMP2 and CMP3 have been
reviously described in patents WO 200182923 and WO 200241835
15, 16]. Compounds CMP1 and CMP4–CMP10 can be prepared
ccording to synthesis methods described in patent WO 05/040212
32]. These patents may be accessed free of charge at http://ep.
spacenet.com.
lasmid Constructs
etails on construction of all prokaryotic and eukaryotic expression
ectors used in this work are included as Supplemental Data. Re-
orter plasmids 7xH1/CRP/SEAP and pCMV-Luc were described
lsewhere [9].
xpression in Bacteria and Purification
f GST-ER-LBD Fusion Proteins
ecombinant GST-ER-LBD fusion proteins have been produced by
sing the protocol detailed in the Supplemental Data.
n Vitro Ligand Binding Assays
igand affinities for the GST-ER-LBD polypeptides were deter-
ined by a competitive radiometric binding assay using tritium-
abeled estradiol (3[H]E2) (Amersham, 158 Ci/mmol, 558 mCi/mg) as
racer. Microplate (Basic Flashplates, NEN) wells were coated for
2 hr at 4°C with 100 l PBS containing anti-GST antibodies (Amer-
ham) at a 5 g/ml concentration. After three washes with 200 l
BS, background was reduced by saturating with 200 l PBS con-
aining 1% BSA for 3 hr at 4°C. Wells were then washed three times
ith 200 l lysis buffer containing 0.1 M NaCl and 0.2% n-Dodecyl
-D-maltoside (assay buffer). Suitable amounts of crude E. coli su-
ernatants containing the GST-ER-LBD proteins (2–10 l) or of
urified polypeptides (8 nM) were bound to anti-GST antibody-
oated wells for 1 hr at 23°C in 200 l assay buffer with constant
gitation. After three more washes with 200 l assay buffer, the
igand binding reaction was set up in 195 l assay buffer containing
–10 nM 3[H]E2 and 5 l DMSO or suitable dilutions of test com-
ounds in DMSO. Incubation was for 2 hr at 23°C with constant
haking, followed by SPA radioactivity measurement using a micro-
late scintillation and luminescence counter (Top Count NXT, Pack-
rd). IC50 values were obtained by multiparameter logistic fitting of
he experimental data with the aid of Kaleidagraph software.
east Strains and Growth Conditions
G-1945 (Clontech) was used as the yeast reporter host strain for
isplay and screening of the library. It contains both HIS3 and lacZ
eporter genes under the control of a GAL4-responsive UAS inte-
rated in the genome. Yeast strain Y187 (Clontech) was instead
sed for quantitative β-galactosidase reporter assays. It contains
nly the lacZ reporter gene, which is expressed at higher levels
han in strain CG-1945. Both strains (gal4−, gal80−) were propa-
ated at 30°C in YPD medium. Yeast strains transformed with
GBT9 plasmids were grown and stored in SD minimal medium
SD, Clontech) supplemented with −Trp amino acid mixture. Growth
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891selection for the nutritional reporter HIS3 was performed on agar
plates in SD supplemented with a −His/−Trp amino acid mixture
and either 15–30 mM (single plasmid transformants) or 70 mM (li-
brary clones pool) 3-amino-1,2,4-triazole (3-AT), a competitive in-
hibitor of HIS3 protein. In vivo β-galactosidase assays were per-
formed on agar plates in SD supplemented with a −Trp amino acid
mixture, X-gal (80 mg/L), and 1× BU salts (10× = 70 g Na2PO4·7H2O
and 30 g NaH2PO4 [pH 7]). Growth selective and X-gal plates were
supplemented with DMSO, E2, or tetrahydrofluorenone compounds
at the indicated concentrations.
Transformation of Yeast Cells
Yeast cells were transformed by using the Li Ac procedure and the
YEASTMAKER Yeast transformation kit (Clontech) and following
the manufacturer’s protocol. For single-plasmid, small-scale trans-
formations, 0.1 g DNA was used to transform 0.1 ml yeast compe-
tent cells, resulting in transformation efficiencies of approximately
105 colony-forming units (cfu) per g of DNA. To set up transfor-
mation conditions for homologous recombination of pGBT9-
GAL4DBD/ERα-LBD L(384)M/VP16AD with mutagenized PCR prod-
ucts, the expression vector was linearized by BglII digestion, and
half of it was treated with Klenow polymerase prior to gel purifica-
tion. A total of 100 ng of each of the two versions of the digested
plasmid were then transformed as outlined with 200 ng, 300 ng, or
400 ng of a 160 bp PCR fragment obtained by using wt oligonucle-
otides corresponding to the degenerated oligonucleotides designed
to construct the mutated library (see below). Cotransformation of 100
ng linearized blunt-ended vector with 300 ng PCR fragment
showed an efficiency of approximately 105 per g of DNA that was
100-fold higher than background with the recipient vector alone.
Based on this condition, in the library-scale transformation pro-
cedure, 60 g mutagenized fragment collection and 20 g linear-
ized blunt-ended recipient vector were used to transform 1 ml yeast
cells with an estimated efficiency of 5 × 104 cfu per g of DNA.
Library Design
Low-energy conformations of CMP1 were calculated by using Ce-
rius2 software (Accelrys, San Diego, US). The three energy mini-
mum CMP1 conformations were manually modeled into the super-
imposed crystal structures of human ERα-LBD (PDB entry 1ERE,
[17]) and human ERβ-LBD (PDB entry 1QKM, [18]) by using the E2
and raloxifene ligands as structural templates.
Library Construction and Selection
Degenerate oligonucleotide mixtures were synthesized by a split-
pool strategy based on the following wt sequences: forward, 5#-GAT
CCTGATGATTGGTCTCGTCTGGCGCTCCATGGAGCACCCAGGGAA
GCTACTGTTTGCTCCTAAC-3#; reverse, 5#-CATCATGCGGAACCG
AGATGATGTAGCCAGCAGCATGTCGAAGATCTCCACCATGCCCTC
TAC-3#. At each of the underlined positions (L391, F404, M421,
I424, L428), the previously synthesized column material was split
into ten individual pools, and the ten possible codons were synthe-
sized separately and the aliquots were pooled together again. Co-
dons used were: GGC(G), GCC(A), TGC(C), GTG(V), ATC(I), CTG(L),
ATG(M), TTC(F), TAC(Y), and TGG(W). A slightly higher quantity of
pooled column material (15% of total) was used to synthesize the
wt codon, thus leaving 9.4% for each of the other nine remaining
codons. This “wt spiking” increased the relative frequency of
clones with a low number of substitutions (one or two) with respect
to clones having four or five substitutions that represent the major-
ity of the library clones. While in a homogeneous “10% library,” the
45 possible single-substitution clones would have represented only
0.045% of the total library; the use of 15% wt codons increases this
fraction to 0.2152%, i.e., the clones were about 5-fold as frequently
represented in the library. Consequently, the fraction of clones with
five substitutions (59,049 possible combinations) dropped from
about 59% to about 44%.
Preparative amounts of mutated LBD fragments were synthe-
sized by PCR amplification of 6 g pGBT9-GAL4DBD/hERα-LBD/
VP16AD DNA template by including 2.1 nmol of each of the degen-
erated oligonucleotide mixes in a total reaction volume of 6 ml con-
taining 250 mM dNTPs, 5% DMSO, 600 l Pfu 10× buffer, and 300
U Pfu polymerase (Stratagene). The PCR amplification consisted of25 cycles at 95°C for 1 min, 65°C for 1 min, and 72°C for 2 min. A
total of 60 g of the mutagenized 160 bp product mixture was puri-
fied on QIAquick spin columns (Qiagen) and was used in a scaled
up cotransformation experiment together with 20 g linearized re-
cipient vector as outlined. A total of 30 ml of the cotransformation
reaction was spread on 20 23 cm × 23 cm −Trp-selective plates,
colonies were harvested after 3 days of growth at 30°C, and 1 ml
glycerol stocks of the amplified library were prepared. Suitable dilu-
tions of the cotransformation mixture were spread onto 100 mm
plates to control the efficiency of homologous recombination and
to determine the library titer (5 × 104 cfu per g of DNA). Glycerol
stocks were also titered and contained 1.2 × 105 cfu per l. A total
of 1 × 105 cfus were spread on each of 20 100 mm −His/−Trp-
selective plates containing 70 mM 3-AT and either 1 M (first ex-
periment) or 10 M (second experiment) CMP1 (a total of 2 × 106
cfus per experiment were plated). After 6 days of growth at 30°C,
the average number of His+ colonies per plate was 200 in the first
experiment and 60 in the second experiment. A total of 80 colonies
out of 200 of the first screening and all colonies of the second
screening were streaked out from each plate on X-gal 100 mm
plates containing either DMSO or CMP1 at the concentration of 1
M or 10 M, respectively (a replica on −Trp master plates was
also performed). After 3 days of growth at 30°C, all clones that were
blue in the presence of the compound and white on control plates
were streaked on X-gal plates containing either DMSO or CMP1 at
a 10-fold lower concentration (here, a replica on −Trp master plates
was also performed). This procedure was reiterated down to a
compound concentration of 0.1 M, at which 28 and 31 indepen-
dent positive clones, respectively, were collected for further
analysis.
Plasmid Rescue from Yeast Clones
Colonies corresponding to the mutants of interest were grown to
saturation at 30°C for 16 hr in 2 ml of −Trp SD. Cells from a 1.3 ml
culture fraction were collected by centrifugation and resuspended
by vortexing in 0.2 ml protoplasting buffer (100 mM Tris-HCl [pH
7.5], 10 mM EDTA, 14.4 mM β-mercaptoethanol) containing 400 l
of a 40 U/l Lyticase (Sigma) solution. After cell walls were dis-
solved by incubation for 2 hr at 37°C, 200 l lysis solution (0.2 M
NaOH, 1% SDS) was added, and samples were incubated at 65°C
for 20 min, and then put rapidly on ice. Samples were mixed with
200 l 3 M K-acetate (pH 5.4), incubated on ice for 15 min, and
spun for 3 min at 13,000 rpm in an Eppendorf microcentrifuge.
Plasmid DNA was recovered from supernatants by precipitation
with 0.6 volumes of isopropanol. Rescued plasmids were both
transformed in electro-competent E. coli DH12S cells and directly
sequenced by PCR amplification of a 360 bp fragment using oligo-
nucleotide primers (5#-CTGACCAACCTGGCAGACAG-3#, forward;
5#-GGACTCGGTGGATATGGTCC-3#, reverse) annealing 100 bp up-
stream and downstream, respectively, of the mutagenized insert.
Amplified fragments were purified on QIAquick spin columns and
subjected to automatic sequencing by using either of two sequenc-
ing primers (5#-GTTCACATGATCAACTGGGCG-3# or 5#-GAGACTT
CAGGGTGCTGGAC-3#) that annealed 70 bp from the mutagenized
insert boundaries.
Yeast Protein Extracts and Western Blot Analysis
The urea/SDS method (Clontech Yeast Protocols Handbook) to
prepare yeast protein extracts suitable to evaluate mutant protein
expression by Western blot analysis by using anti-VP16 AD poly-
clonal antibodies (Santa Cruz) was followed.
Quantitative -Galactosidase Assays
Single colonies were grown to saturation for 16 hr at 30°C in −Trp
SD minimal medium; cells were collected by centrifugation and
then diluted in YPD medium to an optical density of 0.04 at 600
nm. Subcultures of 5 ml volume were set up and allowed to grow
for 7 hr at 30°C in the presence of DMSO or various ligand concen-
trations until they reached mid-log phase (OD600 = 0.4–0.5). Cells
from 1.5 ml of culture (two duplicates per sample) were processed
for quantitative β-galactosidase assays by following the Clontech
Yeast Protocols Handbook procedure as described in the Supple-
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892mental Data. Dose-response data were analyzed by using a nonlin-
ear regression analysis (Kaleidagraph software).
Cell Culture, Transfections, and SEAP Assays
All cell culture experiments were performed by using phenol red-
free Dulbecco’s modified Eagle’s medium (DMEM, GIBCO-BRL)
supplemented with 10% dextran charcoal-treated (Sigma) fetal bo-
vine serum (FBS, GIBCO-BRL).
To evaluate the effect of compounds on the MGR-ERα-LBD chi-
mera transcriptional activity, HeLa cells were seeded 18 hr before
transfection in 6-well plates (3 × 105 cells/well) and transfected with
1 g plasmid DNA per well (0.5 g transactivator + 0.5 g reporter)
by using Lipofectamine (Invitrogen), according to manufacturer’s
instructions. A total of 100 ng of the luciferase reporter plasmid
pCMV-Luc were included in the transfection mixture as an internal
control for transfection efficiency. At 6 hr after transfection, culture
medium was changed, and cells were left untreated or were treated
with the various ligands. After an additional 24 hr, medium was
harvested and analyzed for the activity of human-secreted alkaline
phosphatase (SEAP) by a commercially available assay (Tropix
Phospha-Light system) by following the manufacturer’s guidelines.
Reactions were performed in microplates, and SEAP activity was
measured as light emission by using a microplate scintillation and
luminescence counter (Top Count NXT, Packard). Values were sub-
tracted of the background obtained by measuring endogenous al-
kaline phosphatase in untransfected cell medium and normalized
against luciferase activity measured in cell extracts. Conversion to
SEAP concentration values (ng/ml) was done by standard activity
curves obtained with purified human placental AP (Sigma). Dose-
response data were analyzed as outlined above.
Supplemental Data
Supplemental Data including an additional Experimental Pro-
cedures section and additional results are available at http://
www.chembiol.com/cgi/content/full/12/8/883/DC1.
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